Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity

IF 6.1 2区 医学 Q1 ENGINEERING, BIOMEDICAL
Shiho Chiba, Tadashi Maemura, Kathryn Loeffler, Steven J. Frey, Chunyang Gu, Asim Biswas, Masato Hatta, Yoshihiro Kawaoka, Ravi S. Kane
{"title":"Single immunization with an influenza hemagglutinin nanoparticle-based vaccine elicits durable protective immunity","authors":"Shiho Chiba,&nbsp;Tadashi Maemura,&nbsp;Kathryn Loeffler,&nbsp;Steven J. Frey,&nbsp;Chunyang Gu,&nbsp;Asim Biswas,&nbsp;Masato Hatta,&nbsp;Yoshihiro Kawaoka,&nbsp;Ravi S. Kane","doi":"10.1002/btm2.10689","DOIUrl":null,"url":null,"abstract":"<p>Vaccination is the most effective strategy to combat influenza. Ideally, potent and persistent vaccine effects would be induced with a single vaccine dose. Here, we designed a virus-like particle (VLP)-based vaccine presenting multiple copies of the influenza hemagglutinin (HA) from A/Puerto Rico/8/1934 (PR8HA-VLP) and examined its immunogenicity and protective efficacy in ferrets. Serum-neutralizing antibodies were effectively induced against the homologous virus at 3-week post-vaccination with a single dose of PR8HA-VLP with or without adjuvants. When the single-immunized ferrets were challenged with the homologous virus, virus replication in the nasal mucosa was significantly reduced. Long-term monitoring of serum titers revealed that after adjuvanted vaccination with PR8HA-VLP, neutralizing antibodies were retained at similar levels 20- to 183-week post-vaccination, although a 4- to 8-fold titer decline was observed from 3- to 20-week post-vaccination. Boost immunization at 183 weeks after the first immunization elicited higher neutralizing antibody titers than those at 3 weeks after the initial immunization in most of the animals. These results confirm that nanoparticle-based vaccines are a promising approach to effectively elicit durable multiyear neutralizing antibody responses against influenza viruses.</p>","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"9 5","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/btm2.10689","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/btm2.10689","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Vaccination is the most effective strategy to combat influenza. Ideally, potent and persistent vaccine effects would be induced with a single vaccine dose. Here, we designed a virus-like particle (VLP)-based vaccine presenting multiple copies of the influenza hemagglutinin (HA) from A/Puerto Rico/8/1934 (PR8HA-VLP) and examined its immunogenicity and protective efficacy in ferrets. Serum-neutralizing antibodies were effectively induced against the homologous virus at 3-week post-vaccination with a single dose of PR8HA-VLP with or without adjuvants. When the single-immunized ferrets were challenged with the homologous virus, virus replication in the nasal mucosa was significantly reduced. Long-term monitoring of serum titers revealed that after adjuvanted vaccination with PR8HA-VLP, neutralizing antibodies were retained at similar levels 20- to 183-week post-vaccination, although a 4- to 8-fold titer decline was observed from 3- to 20-week post-vaccination. Boost immunization at 183 weeks after the first immunization elicited higher neutralizing antibody titers than those at 3 weeks after the initial immunization in most of the animals. These results confirm that nanoparticle-based vaccines are a promising approach to effectively elicit durable multiyear neutralizing antibody responses against influenza viruses.

Abstract Image

流感血凝素纳米颗粒疫苗的单次免疫可产生持久的保护性免疫力
接种疫苗是抗击流感的最有效策略。理想的情况是,只需接种一次疫苗就能产生强效和持久的疫苗效果。在此,我们设计了一种以病毒样颗粒(VLP)为基础的疫苗,该疫苗呈现多个来自 A/Puerto Rico/8/1934 的流感血凝素(HA)拷贝(PR8HA-VLP),并在雪貂体中检验了其免疫原性和保护效力。在接种单剂 PR8HA-VLP(含或不含佐剂)3 周后,可有效诱导针对同源病毒的血清中和抗体。单次免疫后的雪貂经同源病毒挑战后,鼻粘膜中的病毒复制明显减少。对血清滴度的长期监测显示,接种 PR8HA-VLP 佐剂疫苗后,中和抗体在接种后 20 到 183 周内保持在相似的水平,但在接种后 3 到 20 周内滴度下降了 4 到 8 倍。在大多数动物中,首次免疫后 183 周的加强免疫比首次免疫后 3 周的中和抗体滴度更高。这些结果证实,基于纳米粒子的疫苗是一种很有前景的方法,可有效激发针对流感病毒的持久的多年中和抗体反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Bioengineering & Translational Medicine
Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
8.40
自引率
4.10%
发文量
150
审稿时长
12 weeks
期刊介绍: Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信